The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer
Gut and Liver
;
: 665-671, 2016.
Article
in English
| WPRIM
| ID: wpr-166362
ABSTRACT
Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, β-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pancreas
/
Pancreatic Neoplasms
/
Adenocarcinoma
/
Aspirin
/
Epidemiology
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Diphosphonates
/
Dipeptidyl-Peptidase IV Inhibitors
/
Metformin
Language:
English
Journal:
Gut and Liver
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS